A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.
about
A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A multi-center phase II study ...... ith metastatic gastric cancer.
@ast
A multi-center phase II study ...... ith metastatic gastric cancer.
@en
type
label
A multi-center phase II study ...... ith metastatic gastric cancer.
@ast
A multi-center phase II study ...... ith metastatic gastric cancer.
@en
prefLabel
A multi-center phase II study ...... ith metastatic gastric cancer.
@ast
A multi-center phase II study ...... ith metastatic gastric cancer.
@en
P2093
P2860
P1433
P1476
A multi-center phase II study ...... ith metastatic gastric cancer.
@en
P2093
Biyun Wang
Fangfang Lv
Huijie Wang
Jialei Wang
Jianhua Chang
Jiliang Yin
Tianshu Liu
Weijian Guo
P2860
P2888
P356
10.1186/S12885-017-3174-Z
P407
P577
2017-03-14T00:00:00Z
P6179
1084250523